Eli Lilly and Company (NYSE:LLY) HOLD
Eli Lilly is the champion of the GLP-1 obesity revolution — tirzepatide, sold as Mounjaro and Zepbound, drives ~two-thirds of revenue and is growing over 50% a year — with quality 84 and a strong driver score of 80. HOLD on every horizon: it trades around 32-40x earnings against a ~23x warranted multiple, so the Valuation-Ceiling gate binds. Great growth, expensive price.
Re-presenting the Donatien Investment report on Eli Lilly (NYSE:LLY), dated 20 July 2026, at US$1146.90. HOLD on the short, medium and long horizons.
The GLP-1 champion
Eli Lilly is one of the world's largest pharmaceutical companies and today the dominant force in the GLP-1 revolution treating obesity and type-2 diabetes. Its crown jewels are tirzepatide — sold as Mounjaro for diabetes and Zepbound for weight loss — which together drive roughly two-thirds of revenue and are growing well over fifty per cent a year. What sets Lilly apart is best-in-class clinical efficacy: its drugs out-perform rivals on weight loss, and it holds around sixty per cent of the US weight-loss market. Business quality is high at eighty-four and the driver score is a strong eighty, with health-care now a macro tailwind.
Great growth, expensive price
The valuation is where a superb franchise becomes only a hold. Lilly trades somewhere around thirty-two to forty times earnings, against a warranted multiple closer to twenty-three times and above the twenty-two-times health-care floor. So the valuation pillar scores just thirty-seven, firmly in the expensive band, and our valuation-ceiling gate binds and caps the signal at hold before any upgrade. This is not a knock on the business — the growth is real and the driver is strong — it is a statement about the entry price: a lot of that future growth is already in the stock.
A hold: momentum and oral competition
Timing and competition round it out. Daily momentum has rolled over, and the timing pillar is a middling fifty-six. And the moat, wide as it is, has a live crack: Lilly is gaining overall but losing the oral sub-segment near-term to Novo Nordisk's oral Wegovy. Layer on US drug-pricing pressure — most-favoured-nation and Medicare measures that could bite margins — and you have the bear case near nine hundred and twenty dollars, roughly a twenty per cent drawdown, where the rich multiple compresses toward the warranted anchor. None of it impairs the franchise; it argues for patience on the entry.
What could go wrong
Losing the oral GLP-1 sub-segment to Novo. US MFN/Medicare drug-pricing bites margins. Rich multiple; bear ~$920 (~-20%).
Risk vs Reward
Against the current US$1,146.9, the report frames a bull case at US$1,450 (+26%), a base case at US$1,290 (+12%) and a bear case at US$920 (-20%). See the full report for the probability weight behind each path.
The verdict
Eli Lilly is the champion of the GLP-1 obesity revolution — tirzepatide, sold as Mounjaro and Zepbound, drives ~two-thirds of revenue and is growing over 50% a year — with quality 84 and a strong driver score of 80. HOLD on every horizon: it trades around 32-40x earnings against a ~23x warranted multiple, so the Valuation-Ceiling gate binds. Great growth, expensive price.
Read the full report on donatien.ca →
